KR970703357A - 병원체-저해제로서의, 측쇄를 가지는 올리고누클레오티드(branched oligonu-cleotides as pathogen-inhibitory agents) - Google Patents

병원체-저해제로서의, 측쇄를 가지는 올리고누클레오티드(branched oligonu-cleotides as pathogen-inhibitory agents) Download PDF

Info

Publication number
KR970703357A
KR970703357A KR1019960706919A KR19960706919A KR970703357A KR 970703357 A KR970703357 A KR 970703357A KR 1019960706919 A KR1019960706919 A KR 1019960706919A KR 19960706919 A KR19960706919 A KR 19960706919A KR 970703357 A KR970703357 A KR 970703357A
Authority
KR
South Korea
Prior art keywords
pathogen
oligonucleotide
sequences
linked
configuration
Prior art date
Application number
KR1019960706919A
Other languages
English (en)
Inventor
어그래왈 서드히어
메쉬위츠 수잔
Original Assignee
다알렌 반스톤
하이브리돈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다알렌 반스톤, 하이브리돈, 인코포레이티드 filed Critical 다알렌 반스톤
Publication of KR970703357A publication Critical patent/KR970703357A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/52—Physical structure branched

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발병은 신규한 안타센스 올리고누클레오티드에 관한 것이다. 본 발병의 올리고누클레오티드는 뉴클레아제 공격에 대하여 증가된 저항성을 가지고, 병원성 감염과의 경쟁에서 증가된 효율을 나타낸다. 본 발병의 올리고누클레오티드는, 병원체의 대사 및/또는 생식에 필수적인 병원체의 핵산 서열에 각각 상보적인, 2개 이상의 동일하거나 또는 다른 서열을 포함한다. 상기 서열은, 단일 병원체내의 동일하거나 다른 표적 핵산에, 동일 병원체의 다른 균주 상의 표적 서열에, 또는 다른 병원체 상의 표적 서열에 상보적일 수 있다. 바람직한 구체예에서, 상기 서열은, 3'-3' 결합을 통하여 커플링되고, 이것은 3' 핵용해 분해를 현저하게 감소시킨다.

Description

병원체-저해제로서의, 측쇄를 가지는 올리고누클레오티드(BRANCHED OLIGONUCLEOTIDES AS PATHOGEN-INHIBITORY AGENTS)
[도면의 간단한 설병]
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 병원체의 표직 서열에 상보적인 2개 이상의 동일한 올리고누클레오티드 서열이 서로 결합되 있는 항-병원체 올리고누클레오티드.
  2. 제1항에 있어서, 상기 올리고누클레오티드 서열이 5' 대 3' 배치로 서로 결합되어 있고, 모든 자연-발생 핵산에서 서로 인접하지 않는 것을 특징으로 하는 항-병원체 올리고누클레오티드.
  3. 제1항에 있어서, 상기 올리고누클레오티드 서열이 3' 대 3', 2' 대 2', 3' 대 2' 또는 2' 대 3' 배치로 서로 결합되어 있는 것을 특징으로 하는 항-병원체 올리고누클레오티드.
  4. 제1항에 있어서, 상기 올리고누클레오티드 서열이 3' 대 3' 배치로 서로 결합되어 있는 것을 특징으로 하는 항-병원체 올리고누클레오티드.
  5. 병원체의 다른 표적 서열에 상보적인 2개 이상의 다른 올리고누클레오티드 서열이 서로 결합되어 있는 항-병원체 올리고누클레오티드.
  6. 제5항에 있어서, 상기 올리고누클레오티드 서열이 5' 대 3' 배치로 서로 결합되어 있고, 모든 자연-발생 핵산에서 서로 인접하지 않는 것을 특징으로 하는 항-병원체 올리고누클레오티드.
  7. 제5항에 있어서, 상기 올리고누클레오티드 서열이 3' 대 3',2' 대 2',3' 대 2' 또는 2' 대 3' 배치로 서로 결합되어 있는 것을 특징으로 하는 항-병원체 올리고누클레오티드.
  8. 제5항에 있어서, 상기 올리고누클레오피드 서열이 3' 대 3' 배치로 서로 결합되어 있는 것을 특징으로 하는 항-벙원체 올리고누클레오티드.
  9. 하나 이상의 올리고누클레오티드 서열이 한 병원체의 표적 서열에 상보적이고, 하나 이상의 올리고누클레오티드 서열이 다른 병원체의 표적 서열에 상보적인 2개 이상의 다른 올리고누클레오티드 서열이 서로 결합되어 있는 항-병원체 올리고누클레오티드.
  10. 제9항에 있어서, 상기 올리고누클레오티드 서열이 5' 대 3'배치로 서로 결합되어 있고, 모든 자연-발생 핵산에서 서로 인접하지 않는 것을 특징으로 하는 항-병원성 올리고누클레오티드.
  11. 제9항에 있어서, 상기 올리고누클레오티드 서열이 3' 대 3', 2' 대 2', 3' 대 2' 또는 2' 대 3' 배치로 서로 결합되어 있는 것을 특징으로 하는 항-병원성 올리고누클레오티드.
  12. 제9항에 있어서, 상기 올리고누클레오티드 서열이 3' 대 3'배치로 서로 결합되어 있는 것을 특징으로 하는 항-병원성 올리고누클레오티드.
  13. 하나 이상의 올리고누클레오티드 서열이 병원체의 한 균주의 표적 서열에 상보적이고, 하나 이상의 올리고누클레오티드 서열이 동일 병원체의 상이한 균주의 표적 서열에 상보적인 2개 이상의 다른 올리고누클레오티드 서열이 서로 결합되어 있는 항-병원체 올리고누클레오티드.
  14. 제13항에 있어서, 상기 올리고누클레오티드 서열이 5' 대 3' 배치로 서로 결합되어 있고, 모든 자연-발생 핵산에서 서로 인접하지 않는 것을 특징으로 하는 항-병원체 올리고누클레오티드.
  15. 제13항에 있어서, 상기 올리고누클레오티드 서열이 3' 대 3', 2' 대2' 3' 대 2' 또는 2' 대 3' 배치로 서로 결합되어 있는 것을 특징으로 하는 항-병원체올리고누클레오티드.
  16. 제13항에 있어서, 상기 올리고누클레오티드 서열이 3' 대 3' 배치로 서로 결합되어 있는 것을 특징으로 하는 항-병원체 올리고누클레오티드.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960706919A 1994-06-01 1995-05-30 병원체-저해제로서의, 측쇄를 가지는 올리고누클레오티드(branched oligonu-cleotides as pathogen-inhibitory agents) KR970703357A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25249494A 1994-06-01 1994-06-01
US08/252,494 1994-06-01
PCT/US1995/006720 WO1995032986A1 (en) 1994-06-01 1995-05-30 Branched oligonucleotides as pathogen-inhibitory agents

Publications (1)

Publication Number Publication Date
KR970703357A true KR970703357A (ko) 1997-07-03

Family

ID=22956248

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960706919A KR970703357A (ko) 1994-06-01 1995-05-30 병원체-저해제로서의, 측쇄를 가지는 올리고누클레오티드(branched oligonu-cleotides as pathogen-inhibitory agents)

Country Status (9)

Country Link
US (1) US6489464B1 (ko)
EP (1) EP0763050B1 (ko)
JP (1) JPH10504184A (ko)
KR (1) KR970703357A (ko)
AT (1) ATE188479T1 (ko)
AU (1) AU2604995A (ko)
CA (1) CA2190998A1 (ko)
DE (1) DE69514351T2 (ko)
WO (1) WO1995032986A1 (ko)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030099959A1 (en) * 1995-04-12 2003-05-29 Kandimalla Ekambar R. Cooperative oligonucleotides
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
KR20000065690A (ko) * 1999-04-08 2000-11-15 박종구 반응 특이성 및 안정성을 개선시킨 안티센스 올리고 뉴클레오타이드, 안티센스 ｄｎａ 및 그 제조방법
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1741781A3 (en) * 2002-02-20 2007-06-06 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003256857A1 (en) * 2002-08-08 2004-02-25 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
CA2528963A1 (en) * 2003-06-27 2005-01-13 Sirna Therapeutics, Inc. Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina)
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1778867B1 (en) 2004-07-01 2010-04-28 Gen-Probe Incorporated Methods and compositions to detect nucleic acids in a biological sample
CA2723726C (en) 2008-05-13 2017-09-12 Michael M. Becker Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences
JP2012509675A (ja) * 2008-11-25 2012-04-26 ジェン−プロウブ インコーポレイテッド 低分子ｒｎａを検出するための組成物および方法、ならびにその使用
WO2011031520A1 (en) 2009-08-27 2011-03-17 Idera Pharmaceuticals, Inc. Composition for inhibiting gene expression and uses thereof
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
US8877722B2 (en) 2011-03-25 2014-11-04 Idera Pharmaceuticals, Inc. Compositions for inhibiting gene expression and uses thereof
DE102015008536A1 (de) 2015-07-02 2017-01-05 Rheinische Friedrich-Wilhelms-Universität Bonn Diskontinuierliche Oligonukleotid-Liganden
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE RELEASE OF OLIGONUCLEOTIDES
AU2017210726B2 (en) * 2016-01-31 2023-08-03 University Of Massachusetts Branched oligonucleotides
KR102475301B1 (ko) * 2016-04-08 2022-12-09 트랜슬레이트 바이오 인코포레이티드 다량체 코딩 핵산 및 그 용도
CA3033368A1 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
SG11202101288TA (en) 2018-08-10 2021-03-30 Univ Massachusetts Modified oligonucleotides targeting snps
CA3174095A1 (en) 2021-06-23 2022-12-29 Vignesh Narayan HARIHARAN Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US4806403A (en) 1987-12-23 1989-02-21 Gilbert Lemire Decorative module having a concave face
EP0402402B1 (en) * 1988-02-26 1995-12-27 Worcester Foundation For Biomedical Research, Inc. Inhibition of htlv-iii by exogenous oligonucleotides
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5215899A (en) * 1989-11-09 1993-06-01 Miles Inc. Nucleic acid amplification employing ligatable hairpin probe and transcription
CA2089476A1 (en) * 1990-08-15 1992-02-16 Bernard Roizman Inhibition of herpesviridae infection by antisense oligonucleotides
EP0656942A1 (en) * 1990-09-21 1995-06-14 University Of Maryland Compositions and methods for inhibiting growth or replication of viruses
CA2126979A1 (en) * 1991-12-31 1993-07-22 Eliezer Rapaport Antiparasitic oligonucleotides active against drug resistant malaria
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
US5543507A (en) * 1992-03-05 1996-08-06 Isis Pharmaceuticals, Inc. Covalently cross-linked oligonucleotides
AU678980B2 (en) * 1992-07-02 1997-06-19 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method of inhibiting viral replication

Also Published As

Publication number Publication date
JPH10504184A (ja) 1998-04-28
CA2190998A1 (en) 1995-12-07
AU2604995A (en) 1995-12-21
US6489464B1 (en) 2002-12-03
EP0763050B1 (en) 2000-01-05
EP0763050A1 (en) 1997-03-19
DE69514351T2 (de) 2000-08-10
DE69514351D1 (de) 2000-02-10
WO1995032986A1 (en) 1995-12-07
ATE188479T1 (de) 2000-01-15

Similar Documents

Publication Publication Date Title
KR970703357A (ko) 병원체-저해제로서의, 측쇄를 가지는 올리고누클레오티드(branched oligonu-cleotides as pathogen-inhibitory agents)
WO1995032986B1 (en) Branched oligonucleotides as pathogen-inhibitory agents
ES2556243T3 (es) Agentes terapéuticos que contienen bacteriófagos
AU8181201A (en) Immunostimulatory oligodeoxynucleotides
CA2202280A1 (en) Sugar modified nucleosides and their use for synthesis of oligonucleotides
ATE138384T1 (de) Olionukleotidalkylphosphonate und - phosphonothioate
DE50214266D1 (de) Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung
CA2457528A1 (en) Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
HUP0002322A2 (hu) Multivalens vakcinakészítmény kevert hordozóval
EP1743901A3 (en) Oligonucleotides having A-DNA or B-DNA form
AU2001290706A1 (en) Antisense modulation of clusterin expression
WO2007112414A3 (en) Conjugated double strand compositions for use in gene modulation
DE69934227D1 (de) Auf beta-arabinose, und dessen analogen, basierte antisense oligonukleotide
BR9809433A (pt) Moléculas de dna enzimáticas
WO2003045965A3 (en) Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
ATE275956T1 (de) Veränderung der dns methyltransferase durch kombinationstherapie
KR960704034A (ko) 단백질 생산, 세포 증식 및(또는) 전염병 병원균의 증식에 대한 올리고뉴클레오티드 저해의 향상법(Enhancement of Oligonucleotide Inhibition of Protein Production, Cell Proliferation, and/or Multiplication of Infectious Disease Pathogens)
SE9503117D0 (sv) Novel use of padlock probes
WO2000040592A8 (en) Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
BR9707400A (pt) Vacinas contra produto do gene 63 de vìrus varicella zoster.
Yamakawa et al. Properties of nicked and circular dumbbell RNA/DNA chimeric oligonucleotides containing antisense phosphodiester oligodeoxynucleotides
Peyrottes et al. Dramatic effect of the anomeric configuration on the thermal stability of duplex formed between novel dodecathymidine phosphoramidate (PNH2) and complementary DNA and RNA strands
Deglane et al. 5-Propynylamino α-deoxyuridine promotes DNA duplex stabilization of anionic and neutral but not cationic α-oligonucleotides
Yamakawa et al. Properties and Anti-HIV Activity of Circular Sense and Antisense Oligonucleotides
DE10051628B4 (de) Einzelsträngiges Oligonukleotid und dessen Verwendung

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid